Raymond James Financial Inc. Acquires Shares of 102,061 Krystal Biotech, Inc. (NASDAQ:KRYS)

Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 102,061 shares of the company's stock, valued at approximately $15,989,000. Raymond James Financial Inc. owned approximately 0.35% of Krystal Biotech at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in KRYS. US Bancorp DE boosted its holdings in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after purchasing an additional 82 shares during the period. Crossmark Global Holdings Inc. lifted its stake in shares of Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock worth $1,822,000 after purchasing an additional 121 shares in the last quarter. Perigon Wealth Management LLC increased its position in Krystal Biotech by 1.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after buying an additional 123 shares during the last quarter. Finally, Xponance Inc. raised its holdings in Krystal Biotech by 9.5% during the fourth quarter. Xponance Inc. now owns 1,785 shares of the company's stock valued at $280,000 after buying an additional 155 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS traded down $1.35 during trading hours on Friday, reaching $167.77. The stock had a trading volume of 83,360 shares, compared to its average volume of 295,101. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The business's fifty day moving average is $176.14 and its two-hundred day moving average is $171.62. The company has a market cap of $4.85 billion, a price-to-earnings ratio of 56.56 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the previous year, the business earned $0.30 EPS. The firm's revenue was up 116.4% on a year-over-year basis. Sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KRYS has been the subject of several analyst reports. Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $220.00.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).